Kornimate/medical-research-clean huggingface dataset:
does straight catheterization in short gynecologic procedures cause bacteriuria?

Conditions: Postoperative Bacteriuria

Summary: this is a prospective randomized controlled trial to look into the reduction of catheter associated urinary tract infections in the postoperative period. it will specifically look at short gynecologic procedures such as d\&c (dilation and curettage), hysteroscopies and leep procedures and the need to perform intraoperative catheterization. if a patient urinates immediately before a short operation then there is no need to drain the bladder with a catheter during the procedure. the investigators hypothesize that eliminating catheterization during these short procedures may decrease postoperative urinary tract infections. the hope is that this study would provide evidence to support a change in practice.

the majority of research currently concentrates on indwelling catheters rather than one-time catheterization. current practice at our institution in the gynecologic operating room is to perform a one time catheterization on patient's undergoing short procedures, yet it is unclear if this is a necessary intervention. if patients are asked to void immediately before their procedure it would eliminate the need for intra-operative catheterization and eliminate a potential source of infection. the study is designed to determine whether routine catheterization prior to a minor ob/gyn procedure causes symptomatic or asymptomatic bacteria in the urine. current practice is one-time catheterization of patients undergoing minor ob/gyn procedures prior to the beginning of the procedure. the investigators hypothesize that this causes asymptomatic or symptomatic bacteriuria.

Eligibility criteria:
inclusion criteria: * the patient must be 18 years of age or older. * the patient must be female. * the patient must be undergoing a same-day gynecologic procedure where catheterization is usually performed. * the patient must have general anesthesia or monitored anesthesia care (mac). this includes iv sedation. exclusion criteria: * the patient cannot be undergoing intermittent one-time catheterization. * the patient can not have had an indwelling catheter placed in the past 6 months. * the patients cannot have a concomitant pelvic infection. * the procedure cannot require spinal anesthesia. * the patient cannot be taking immunosuppressive medications. * the patient cannot be taking antibiotics and/or suppressive therapy for chronic urinary tract infections. * the patient cannot receive pre-operative or intra-operative antibiotics.

Keywords: bacteriuria straight catheterization urinary tract infections iatrogenic
characteristics of mediastinal lymph node with false positive fdg pet/ct results in lung cancer staging : relation with tb and latent tb infection

Conditions: Lung Cancer

Summary: the purpose of this study is to analyze pathologic and radiologic characteristics of mediastinal lymph nodes with false positive fdg pet/ct results in lung cancer staging and assess relationship between false positive mediastinal lymph node and tb/latent tb.


Eligibility criteria:
inclusion criteria: * age 20-75, men and women * person who performed pet/ct and surgical biopsy of mediastinal lymph node for diagnosis of primary lung cancer of metastatic lung cancer exclusion criteria: * age \< 20 * person who don't agree with enrollment * illiterate * person who is diagnosed as active tuberculosis now * person who has history of hypersensitivity on ppd (tuberculin purified protein derivative) * pregnant woman * person who is treated as active tuberculosis

Keywords: mediastinal lymph node with false positive fdg pet/ct results in lung cancer staging
construction and evaluation of china's advanced pancreatic tumor big data center

Conditions: Pancreatic Neoplasms

Summary: this study is a multi-center observational study. the start time for data collection is august 31, 2019. patients who have been treated at our institution from august 31, 2019, who were diagnosed with pancreatic tumors on or before august 31, 2019 (diagnosed in our hospital or outside hospitals) would all meet the inclusion conditions of the study and be considered enrollment. patients' baseline and treatment data will be collected under informed concent. the combination of medical big data governance and the leading technology of the big data platform uses real world data to improve the quality and efficiency of pancreatic tumor diagnosis, treatment and scientific research.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18, both male and female; 2. patients with primary pancreatic tumor diagnosed by histology, cytology or imaging; 3. clinical or pathological staging is locally advanced or metastatic pancreatic tumor (newly diagnosed or after surgery and other treatments); 4. you can accept or have not received surgery, chemotherapy, radiotherapy, local treatment or traditional chinese medicine for tumors; 5. the subject voluntarily joined the study and signed an informed consent form voluntarily. exclusion criteria: 1. pancreatic tumors are evaluated as metastatic lesions, not primary tumors of the pancreas.
multicenter study to investigate ser120 nasal spray formulations in patients with nocturia

Conditions: Nocturia

Summary: the purpose of this study is to investigate the efficacy and safety of ser120 nasal spray formulations in patients with nocturia for a total duration of 14 weeks.


Eligibility criteria:
inclusion criteria: * male and female 50 years or older * nocturia of 6 or more months duration averaging greater than 2 nocturic episode per night exclusion criteria: * chf * diabetis insipidus * renal insufficiency * hepatic insufficiency * incontinence * illness requiring systemic steroids * malignancy within the past 5 years * sleep apnea * nephrotic syndrome * unexplained pelvic mass * urinary bladder neurological dysfunction * urinary bladder surgery or radiotherapy * pregnant or breast feeding
re-craniotomy and complications after elective neurosurgery

Conditions: Brain Tumor; Brain Metastases; Brain Cancer; Brain Neoplasms

Summary: this study is a prospective cohort study to find the incidence of re-craniotomy and predictive factors. the secondary outcomes are to find the incidence of major non-neurological complications and predictive factors.

demographic data include age, gender, preoperative neurological assessment, diagnosis, operation, surgical position, asa physical status, dexamethasone requirement, anticonvulsant therapy, airway assessment, and blood component reservation. intraoperative information contain anesthetic technique, total dosage of propofol, fentanyl, and other anesthetic agents, total blood loss, types and amount of fluid replacement, volume of blood transfusion, latest body temperature, and the ability of safe extubation. postoperative complications will be categorized in to general conditions, neurological complications, and systemic problems. general conditions such as on endotracheal tube overnight and postoperative blood transfusion. neurological complications include worsen increased icp, intracranial hematoma, seizures, newly-developed motor deficit, cranial nerve palsy, csf rhinorrhea, and emergency re-craniotomy. systemic problems are hypothermia, electrolyte imbalance, anemia, hypertension, and hyperglycemia. postoperative nausea and vomiting and the rescued anti-emetic drugs will be recorded. postoperative anti-epileptic drug (aed) and pain medication will be collected.

Eligibility criteria:
inclusion criteria: * patients who are scheduled for elective craniotomy during 2017-2019 * patients who are planned for general anesthesia * patients have read the study information and signed in the consent form exclusion criteria: * patients who are unable to understand and sign in the consent form * patients who are scheduled for minor surgical procedures such as ventriculostomy and vp-shunt

Keywords: re-craniotomy major non-neurological complications neurosurgery brain tumors
edible oils in the treatment of constipation of hemodialysis patients

Conditions: Chronic Kidney Disease

Summary: the purpose of this study was to evaluate the effect of olive oil and flaxseed oil in the treatment of constipation of patients undergoing hemodialysis.


Eligibility criteria:
inclusion criteria: * constipated patients by rome iii criteria * hemodialysis \> 3 months exclusion criteria: * diagnosis of gastrointestinal disease other than constipation * previous intolerance to the oils used in the study * cognitive limitations

Keywords: constipation rome iii criteria hemodialysis
comparing chemoprevention drugs for school-based malaria control

Conditions: Malaria,Falciparum; Anemia in Children

Summary: this is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies arm 1: intermittent preventive treatment with dihydroartemisinin-piperaquine (ipt-dp). arm 2: intermittent preventive treatment with sulfadoxine-pyrimethamine (sp) plus chloroquine (cq) (ipt-spcq). arm 3: control - students will receive standard of care (no preventive treatment). outcomes include p. falciparum infection and parasite density, anemia, cognitive function and educational testing, as well as infection prevalence in young children sleeping student's households to assess the impact on transmission.

students attending a single primary school in machinga district, malawi who were enrolled in nct05244954 were offered enrollment in this follow-on study. the intervention will be conducted every 6-weeks during the two school terms which coincide with peak malaria transmission. students in the ipt-dp arm will be treated with with dihydroartemisinin-piperaquine (dp) (females less than 10 years old and all males) or chloroquine (females 10 years old or older. students in the ipt-spcq arm will be treated with sulfadoxine-pyrimethamine plus chloroquine (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).

Eligibility criteria:
inclusion criteria: students (enrolled in the primary intervention) * previously enrolled in nct05244954 * currently enrolled in the study school * plan to attend the study school for the remainder of the school year * parent/guardian available to provide written informed consent younger children in participant households (enrolled in the household prevalence survey) * slept in the household for most nights in the last month * age 6-59 months * parent/guardian available to provide written informed consent exclusion criteria: students (enrolled in the primary intervention) * current evidence of severe malaria or danger signs * known adverse reaction to the study drugs * history of cardiac problems or fainting * taking medications known to prolong qt * family history of prolonged qt * taking trimethoprim-sulfamethoxazole aka bactrim or cotrimoxazole * epilepsy * psoriasis household members (enrolled in the household prevalence survey) * household with more than one school-age child enrolled in the study * current evidence of severe malaria or danger signs

Keywords: malaria school chemoprevention preventive treatment education cognitive function adolescent hemoglobin
efficacy and safety of topical application of tranexamic acid for saving blood losses in patients subjected to prosthetic knee surgery

Conditions: Osteoarthritis, Knee

Summary: to compare the efficacy and safety of topical tranexamic acid versus placebo in patients diagnosed with severe knee osteoarthritis who will undergo prosthetic knee surgery in terms of saving blood loss (estimated blood loss, decreased hemoglobin and decrease in hematocrit).

tranexamic acid (amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin. tranexamic acid binds to plasminogen when it is transformed into plasmin. the activity of the tranexamic acid-plasmin complex on fibrin activity is less than the activity of free plasmin alone. there are two methods of presentation: one, as an injectable solution; two as a clear, colorless aqueous solution. tranexamic acid in spain is approved for use in the prevention and treatment of bleeding due to general fibrinolysis. as for its specific indications the investigators find that it is used for the treatment of metrorrhagia, menorrhagia, gastrointestinal hemorrhage, urinary hemorrhagic disorders after prostate surgery, surgery of ears, nose, throat, gynecological, thoracic, abdominal or cardiovascular or to counter associated hemorrhages to the administration of a fibrinolytic drug.

Eligibility criteria:
inclusion criteria: * patients of both sexes, in the age group: ≥18 and ≤80 years. * patients diagnosed with confirmation of severe knee osteoarthritis according to kellgren criteria (equal or greater than 2) and eva greater than 7, who will be subjected to knee arthroplasty surgery. * patients signing informed consent, agreeing to participate in the study. exclusion criteria: * patients with concomitant cardiac disease: unstable angina pectoris, acute myocardial infarction, atrial fibrillation, flutter, history of sudden death, severe valve insufficiency. * patients with concomitant previous thromboembolic disease: deep venous thrombosis, pulmonary thromboembolism, thrombotic arterial embolism, ischemic vascular cerebral stroke, fibrinolytic diseases after consumption coagulopathy. * hypersensitivity to tranexamic acid. * severe systemic disease: cardio-pulmonary, neurological, renal, infectious or any other type that may impede the development of the study or evaluation of the results. * history of seizures. * patients with severe mental disorder (psychotic disorder, risk of autolysis, manic episode), dependence on toxic substances and / or some physical or psychological limitation to answer. * patients receiving oral anticoagulants. * patients in litigation for disability claim related or not with the disease. * patients who cannot make the necessary visits to carry out the study. * patients who refuse to participate or sign informed consent. * pregnant and lactating patient's period.

Keywords: osteoarthritis tranexamic acid
prosthetic valve and graft endocarditis with mycobacterium chimaera

Conditions: Mycobacterium Chimaera Infections

Summary: mycobacterium chimaera infections have occurred in post-cardiac surgery patients in association with contaminated cardiac bypass heater-cooler devices. so far optimal therapeutical concepts are not clear. at the university hospital basel mycobacterium chimaera- infected protheses are replaced to decrease pathogenic burden and to support antibiotic long- term treatment. this study is to analyze the efficacy of this therapeutic approach.


Eligibility criteria:
inclusion criteria: * patients with mycobacterium chimaera infections after cardiac surgery at university hospital basel exclusion criteria: * none

Keywords: cardiac bypass heater-cooler devices cardiac surgery
family motivational intervention in schizophrenia

Conditions: Cannabis; Schizophrenia

Summary: cannabis use by people with schizophrenia is associated with family distress and poor clinical outcomes. therefore, an family motivational intervention (fmi) was developed to help parents to motivate their child with a diagnoses of recent-onset schizophrenia to reduce cannabis use. in a single-blind randomised clinical trail with 75 patients with the diagnosis of schizophrenia, parents will be assigned to either fmi or to routine care. assessments will be conducted at baseline and at a 10- and 22-month follow-up. the study hypothesis is that fmi will be more effective than routine care in reducing (a) cannabis use in patients and (b) distress and sense of burden in parents.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of schizophrenia or psychotic-related disorder * onset of schizophrenia or related disorder within pervious the 10 years * cannabis use at least 2 days per week in the 3 months prior to the assessment * antipsychotic medication in prescribed or indicated * at least 10 hours of contact with the parents each week in the last month exclusion criteria: -

Keywords: family intervention recent-onset schizophrenia motivational interviewing cannabis use
imipenem and sulbactam in the treatment of imipenem-resistant acinetobacter baumannii bacteremia

Conditions: Acinetobacter Bacteraemia

Summary: infections caused by imipenem-resistant acinetobacter baumannii are associated with high mortality and morbidity. the treatment choices for this resistant pathogen are limited. the objective of the present proposal is to evaluate the effectiveness of combination therapy of imipenem and sulbactam in patients contracted with a. baumannii, and to correlate the clinical effect with the in vitro synergistic results.

acinetobacter baumannii has been increasingly reported in the outbreak of nosocomial infections in the intensive care units, which not only prolong the length of hospital stay but result in high attributable mortality. with its intrinsic resistance to many antimicrobial agents and rapid acquirement of resistance mechanism, resistance to carbapenems, which is often accompanied with resistance to multiple drugs, has emerged worldwide. the limited treatment choice included tigecycline, colistin, and sulbactam. however, the low serum level and bacteriostatic nature of tigecycline hamper its application in blood stream infection, one of the most common presentations of a. baumannii infections. the nephrotoxicity and neurotoxicity of intravenous colistin have caused great concerns in critically ill patients whereas immediate bronchospasm after inhalation and significant clinical consequences have been reported. sulbactam has been used for decades in combination of ampicillin and well tolerated. however, the emergence of resistance strains and discourage of monotherapy in severely ill patients make combination an attractive choice. combination of sulbactam and carbapenems has good synergism against a. baumannii with elevated minimal inhibitory concentration (mic) of sulbactam and/or carbapenems while in an animal model using a. baumannii with higher mic of both sulbactam and meropenem, survival rate was higher in combination group than sulbactam or meropenem-treated alone group. the similar in vivo bactericidal effect was also observed in combination of imipenem and sulbactam. despite plenty of in vivo and in vitro studies mentioned above, the clinical studies were limited. besides, the information regarding the correlation of in vitro synergistic effect of carbapenem and sulbactam with the clinical effect is rarely mentioned. therefore, our study is aimed to evaluate the effectiveness of combination therapy of imipenem and sulbactam in patients contracted with a. baumannii, and to correlate the clinical effect with the in vitro synergistic results

Eligibility criteria:
inclusion criteria: * elder than 18 years old are included if they have bloodstream infections due to a. baumannii regardless of primary infection sites exclusion criteria: * pregnancy or lactation in women * history of serious allergy or intolerance to study drug therapy

Keywords: carbapenem sulbactam acinetobacter baumannii
acid tranexamic effectiveness in reducing the intraoperative bleeding in palatoplasty

Conditions: Cleft Palate; Hemorrhage

Summary: randomized study evaluating the role of tranexamic acid in reducing intraoperative bleeding in palatoplasty.

double-blind randomized study comparing intraoperative bleeding in palatoplasty between patients who received tranexamic acid at a dose of 10mg / kg bolus followed by continuous infusion of 1 mg / kg / h until the end of the procedure and patients receiving placebo in similar arrangements. besides the impact on the volume of intraoperative bleeding the incidence of postoperative wound dehiscence in the first week and the incidence of oronasal fistulas after 1 month were evaluated.

Eligibility criteria:
inclusion criteria: * palatoplasty indication in patients of any age with presence of congenital cleft palate (with or without associated cleft lip), in the study hospital exclusion criteria: * preoperative hemoglobin lower than 10 mg / dl or platelet count less than 100,000 / mm3 ; * presence of coagulopathy caused by known coagulation cascade disorders or systemic diseases, or excessive bleeding history on previous occasions; * history of bleeding disorders in first-degree relatives; * use of medications that may interfere with the coagulation cascade (platelet inhibitors or anticoagulants); * indication of secondary palatoplasty with the purpose of correction oro-nasal fistula; * known allergy to tranexamic acid.

Keywords: cleft palate hemorrhage palatoplasty
an open label trial to evaluate the efficacy and safety of prax-628 in adults with focal onset or tonic-clonic seizures

Conditions: Focal Onset Seizure; Primary Generalized Epilepsy

Summary: an open label clinical trial to evaluate the efficacy and safety of prax-628 in adult patients with focal onset or primary generalized tonic-clonic seizures

an open label clinical trial to evaluate the efficacy and safety of prax-628 in adult patients with focal onset or primary generalized tonic-clonic seizures who can attest to concurrently taking at least 1, but no more than 3 acceptable anti-seizure medications.

Eligibility criteria:
inclusion criteria: * a diagnosis of focal onset seizures or idiopathic generalized tonic clonic seizures. * evidence by computed tomography (ct) or magnetic resonance imaging (mri) in the past that has ruled out a progressive cause of epilepsy. * participant must have been receiving stable doses of allowable asms (a minimum of 1 and a maximum of 3 asms). * participant and/or caregiver (if applicable) self-reports at least 2 countable focal onset seizures per month for focal onset patients, or 1 countable generalized tonic-clonic seizure per month in the 3 months immediately prior to the screening/observation period for pgtcs patients. exclusion criteria: * history of pseudo or psychogenic seizures, or cluster seizures only, within the 12-month period preceding study entry where the individual seizures cannot be counted, or an episode of convulsive status epilepticus requiring hospitalization and intubation in the 12 months prior to screening. * planned epilepsy surgery during the course of the clinical trial. * history of neurosurgery for seizures \<1 year prior to enrollment, or radiosurgery \<2 years prior to enrollment. * schizophrenia and obsessive-compulsive disorder, or other serious mental health disorders. * active suicidal plan/intent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt. * participants with a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years are excluded. * history of cardiac disease(s)/cardiac conduction disorders/or cardiac structural abnormality(ies). * is pregnant or breastfeeding at the time of screening, or has a positive serum pregnancy test at screening or is planning to become pregnant during the clinical trial or within 14 days of the last study drug dose. * has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to screening, or any prior use of gene therapy. * vigabatrin: use in the last 5 years without stable visual fields tested twice over the 12 months after the last dose of vigabatrin. * felbamate: if used as a concomitant asm, patients must be on felbamate for at least 2 years, with a stable dose for 2 months prior to screening. if a patient received felbamate in the past, it must have been discontinued 2 months prior to screening.

Keywords: focal onset seizure primary generalized epilepsy tonic-clonic